YaoGeJu

Public drug landscapesDrug landscape

Dronedarone Hydrochloride Tablets

As of 13 November 2026, for Dronedarone Hydrochloride Tablets, 4 applications are listed as under review at China's CDE; 3 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 8 holders.

Companies, stages and changes, with each record available on this page.

Listed in the US FDA Orange Book as MULTAQ (NDA 022425, SANOFI AVENTIS US LLC).

Last 90 days: Accepted: 2 applications

Current coverage may be incomplete

Follow for free
Complete CDE snapshot
2026/11/13 06:42
Matching scope
Same generic name; dosage forms and combinations kept separate

US Orange Book listing

The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.

Orange Book source export date: 2026/11/06. Version: 2026-11-06.

Showing 1 of 1 distinct brand names.

A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.

Verified official English dosage form: Tablets. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.

Same dosage form

Brand nameApplicant (source text)Application numberDosage form (source text)Route (source text)Marketing status (source text)Approval date
MULTAQ SANOFI AVENTIS US LLC NDA 022425 · Product no. 001 TABLET ORAL HUMAN PRESCRIPTION DRUG 2009/07/01

Other dosage forms of the same ingredient

No listings in this group among the displayed brand names.

Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.

Ingredient cross-list details ↗

Which companies are listed, and at what stages?

Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.

Chemical-drug catalogue

Loaded records: 8 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 6 in the new chemical-registration-classification generic category. Category counts may overlap.

Marketing authorization holderManufacturerApproval numberApprovedStrength / specificationCatalogue category (source text)View source
Qilu Pharmaceutical Co., Ltd.Qilu Pharmaceutical Co., Ltd.国药准字H202548152025/07/08See sourceGeneric approved under the new chemical-drug registration classificationCDE
Shijiazhuang No.4 Pharmaceutical Co., Ltd.Shijiazhuang No.4 Pharmaceutical Co., Ltd.国药准字H202540752025/05/13See sourceGeneric approved under the new chemical-drug registration classificationCDE
Jiangxi Ke Rui Pharma Co., Ltd. romanizedJiangxi Ke Rui Pharma Co., Ltd. romanized国药准字H202538902025/04/15See sourceGeneric approved under the new chemical-drug registration classificationCDE
Shandong Xin Shi Dai Pharma Co., Ltd. romanizedShandong Xin Shi Dai Pharma Co., Ltd. romanized国药准字H202537352025/03/25See sourceGeneric approved under the new chemical-drug registration classificationCDE
Jiangsu Li Tai Er Pharma Co., Ltd. romanizedJiangsu Li Tai Er Pharma Co., Ltd. romanized国药准字H202435152024/04/17See sourceGeneric approved under the new chemical-drug registration classificationCDE
CSPC OUYI PHARMACEUTICAL CO., LTD.CSPC OUYI PHARMACEUTICAL CO., LTD.国药准字H201932912022/11/10See sourceDrug that passed quality-and-efficacy consistency evaluationCDE
Sanofi-Aventis U.S., LLCSanofi Winthrop Industrie国药准字HJ202100842021/12/20See sourceImported originator drugCDE
Anhui Ai Li De Pharmaceutical Co., Ltd. romanizedAnhui Ai Li De Pharmaceutical Co., Ltd. romanized国药准字H202647012026/06/10See sourceGeneric approved under the new chemical-drug registration classificationCDE

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

NHSA drug codes

Loaded records: 7 distinct approval numbers and 7 companies.

Company / applicantApproval numberStrength / specificationNHSA classNHSA drug codeView source
Shijiazhuang No.4 Pharmaceutical Co., Ltd.国药准字H20254075See sourceNot stated by sourceXC01BDJ205A001010102763NHSA
CSPC OUYI PHARMACEUTICAL CO., LTD.国药准字H20193291See sourceNot stated by sourceXC01BDJ205A001010102770NHSA
Qilu Pharmaceutical Co., Ltd.国药准字H20254815See sourceNot stated by sourceXC01BDJ205A001010104021NHSA
Shandong Xin Shi Dai Pharma Co., Ltd. romanized国药准字H20253735See sourceNot stated by sourceXC01BDJ205A001010104188NHSA
Jiangsu Li Tai Er Pharma Co., Ltd. romanized国药准字H20243515See sourceNot stated by sourceXC01BDJ205A001010182291NHSA
Sanofi Aventis U.S., LLC国药准字HJ20210084See sourceNot stated by sourceXC01BDJ205A001010183961NHSA
Jiangxi Ke Rui Pharma Co., Ltd. romanized国药准字H20253890See sourceNot stated by sourceXC01BDJ205A001010184736NHSA
CSPC OUYI PHARMACEUTICAL CO., LTD.国药准字H20193291See sourceNot stated by sourceXC01BDJ205A001010202770NHSA
Shandong Xin Shi Dai Pharma Co., Ltd. romanized国药准字H20253735See sourceNot stated by sourceXC01BDJ205A001010204188NHSA
Sanofi Aventis U.S., LLC国药准字HJ20210084See sourceNot stated by sourceXC01BDJ205A001010283961NHSA
Shandong Xin Shi Dai Pharma Co., Ltd. romanized国药准字H20253735See sourceNot stated by sourceXC01BDJ205A001010304188NHSA
Shandong Xin Shi Dai Pharma Co., Ltd. romanized国药准字H20253735See sourceNot stated by sourceXC01BDJ205A001010404188NHSA

Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.

Current under-review applications

Loaded records: 4 filings and 4 distinct first applicants.

Generic 4

Current under-review applications
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Chengdu Bai Yu Pharmaceutical Co., Ltd. romanized; Chengdu Di Yi Pharmaceutical Co., Ltd. romanizedCYHS2602341Generic2026/09/20Not stated by sourceCDE
Shijiazhuang Shi Hua Xin Pharma Co., Ltd. romanizedCYHS2600036Generic2026/01/06Not stated by sourceCDE
Nan Tong Hui Ju Pharmaceutical Co., Ltd. romanizedCYHS2602585Generic2026/10/21Not stated by sourceCDE
Zhejiang Zhong Yan Pharmaceuticals Technology Co., Ltd. romanized; Qingdao Huang Hai Pharmaceutical Co., Ltd. romanizedCYHS2503637Generic2025/10/12Not stated by sourceCDE
New generic filings in 2026

Loaded records: 3 filings and 3 distinct first applicants.

New generic filings in 2026
Company / applicantAcceptance numberApplication typeAcceptedStrength / specificationView source
Chengdu Bai Yu Pharmaceutical Co., Ltd. romanized; Chengdu Di Yi Pharmaceutical Co., Ltd. romanizedCYHS2602341Generic2026/09/20Not stated by sourceCDE
Shijiazhuang Shi Hua Xin Pharma Co., Ltd. romanizedCYHS2600036Generic2026/01/06Not stated by sourceCDE
Nan Tong Hui Ju Pharmaceutical Co., Ltd. romanizedCYHS2602585Generic2026/10/21Not stated by sourceCDE
API registrations

Non-component matches: 6 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.

NameCompany / applicantRegistration numberStatusName matchSource update dateView source
盐酸决奈达隆 · No verified English nameChongqing Rui Po Lai Pharmaceutical Co., Ltd. romanizedY20250000798IExact ingredient2025/11/10CDE
盐酸决奈达隆 · No verified English nameAnhui Ai Li De Pharmaceutical Co., Ltd. romanizedY20240001285AExact ingredient2026/07/16CDE
盐酸决奈达隆 · No verified English nameShandong Xin Shi Dai Pharma Co., Ltd. romanizedY20240000678AExact ingredient2026/03/16CDE
盐酸决奈达隆 · No verified English nameHebei Guo Long Pharmaceutical Co., Ltd. romanizedY20230000733AExact ingredient2026/02/28CDE
盐酸决奈达隆 · No verified English nameAurore Pharmaceuticals Private LimitedY20220000934AExact ingredient2026/06/09CDE
盐酸决奈达隆 · No verified English nameJiangsu Hui Ju Pharma Co., Ltd. romanizedY20220000297AExact ingredient2025/09/26CDE
盐酸决奈达隆 · No verified English nameCSPC OUYI PHARMACEUTICAL CO., LTD.Y20170001272AExact ingredient2026/03/11CDE

A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.

What changed recently?

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.

Trial registration does not mean an application will follow.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

  1. 2026/10/21Accepted

    Nan Tong Hui Ju Pharmaceutical Co., Ltd. romanized

    CYHS2602585

    Fact date: 2026/10/21 · Site observation date: 2026/10/21

    View source ↗
  2. 2026/09/20Accepted

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

Full API register
Last successful update: 2026/11/13 06:41
NHSA drug codes
Last successful update: 2026/11/05 06:45

The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.

NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Drug Clinical Trial Registry and Information Disclosure Platform
Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete

Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.

Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Free follow

Follow changes to Dronedarone Hydrochloride Tablets

Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.

Confirmation links expire in 7 days. No digest is sent before confirmation; existing follows are not duplicated.

Sign in to choose products